{'fraction_non_alphanumeric': 0.02988691437802908, 'fraction_numerical': 0.011308562197092083, 'mean_word_length': 5.8076923076923075, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization.

OBJECTIVES AND RATIONALE
Negative enhancement of implanted liver tumors has been achieved in preclinical studies on manganese dipyridoxal-diphosphate (Mn-DPDP), a new hepatobiliary specific contrast agent for magnetic resonance imaging (MRI). The authors investigated the effects of Mn-DPDP on primary liver cancer and its possible mechanisms.


METHODS
Magnetic resonance imaging was performed in 15 rats with chemically induced hepatocellular carcinoma (HCC) before and after Mn-DPDP injection. Both tumor-liver contrast-to-noise ratio and absolute tumor enhancement were evaluated and compared with the MRI results of a nonspecific contrast agent, gadolinium-DOTA, and correlated with corresponding microangiographic and histologic findings.


RESULTS
Mn-DPDP injection led to a persistent positive enhancement in differentiated solid HCCs (22/23) with maximal conspicuity at 24 hours. Undifferentiated HCCs were all delineated by a prompt negative enhancement (20/20) with maximal conspicuity within 30 minutes.